A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.

@article{Chapple2005ACO,
  title={A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.},
  author={Christopher R Chapple and Roberto Mart{\'i}nez-Garc{\'i}a and Lucio Selvaggi and Philip Toozs-Hobson and Wolfgang Warnack and Ted Drogendijk and Dawn M Wright and John Bolodeoku},
  journal={European urology},
  year={2005},
  volume={48 3},
  pages={464-70}
}
OBJECTIVE To compare two new generation antimuscarinics at their recommended doses for treatment of overactive bladder syndrome (OAB). METHODS A prospective, double blind, double-dummy, two-arm, parallel-group, 12-week study was conducted to compare the efficacy and safety of solifenacin 5 or 10 mg and tolterodine extended release (ER) 4 mg once daily in OAB patients. After 4 weeks of treatment patients had the option to request a dose increase but were dummied throughout as approved product… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 98 extracted citations

Similar Papers

Loading similar papers…